Prescription medicine
Meloxicam Brand names: Qamzova, Xifyrm, Zybic; first approved as Mobic
Meloxicam (Mobic) is a prescription medicine with an FDA approval on record since 2000. FDA's NDC Directory lists it from 43 generic labelers, and pharmacies paid $0.0166 per meloxicam 7.5 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the meloxicam FDA label on DailyMed (effective January 29, 2026, PD-Rx Pharmaceuticals, Inc.); the NDA 20938 record on Drugs@FDA; every meloxicam label on DailyMed.
Highlights of the record
FDA label of January 29, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS.
Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions (5.1)]. Meloxicam tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)]. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions (5.2)]. WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. […]
Used for
From the label: indications and usageINDICATIONS AND USAGE Meloxicam tablets are a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) (1.1) Rheumatoid Arthritis (RA) (1.2) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg (1.3) 1.1 Osteoarthritis (OA) Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1)].
Forms and strengths
- 5 mg
- 7.5 mg
- 10 mg
- 15 mg
- 7.5 mg/5ml
- 30 mg/ml
Tablet; capsule; suspension; injection.
On the market
- Earliest approval on file
- April 13, 2000 Mobic, Boehringer Ingelheim; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 25 first July 19, 2006; 14 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 48 of which 43 under generic applications, 4 under brand applications, repackagers included
- Last listed patent
- July 31, 2041 Xifyrm injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.0166 per tablet Meloxicam 7.5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 3 since 2012 0 Class I among all firms' recalls; latest January 26, 2022; 2 more by firms not listed as its makers
- FAERS reports
- 57,757 through July 30, 2026
What is meloxicam used for?
From the label: indications and usageINDICATIONS AND USAGE Meloxicam tablets are a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) (1.1) Rheumatoid Arthritis (RA) (1.2) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg (1.3) 1.1 Osteoarthritis (OA) Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1)]. 1.2 Rheumatoid Arthritis (RA) Meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1)]. 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh ≥60 kg [see Dosage and Administration (2.4) and Clinical Studies (14.2)]. […]
Conditions named in the indications of meloxicam's FDA labels, with every medicine labeled for each:
From other meloxicam labelsPain: Meloxicam is indicated for management of osteoarthritis pain.
FDA pharmacologic class: Nonsteroidal Anti-inflammatory Drug.
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
What does the patient leaflet for meloxicam say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?NSAIDs can cause serious side effects, including: Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase: Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines: NSAIDs should only be used:
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
Is there a generic for meloxicam (Mobic)?
The FDA approved the first generic meloxicam on July 19, 2006. 25 generic applications are approved; 14 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists meloxicam from 43 labelers under a generic (ANDA) application and from 4 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Mobic tablets; a patent listed only for Xifyrm injection runs to July 31, 2041. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2000 earliest approval on file
- 2006 first generic approved
- 2041 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for meloxicam (Mobic)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.0166 per Meloxicam 7.5 mg tablet, about the same as a year earlier. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Meloxicam 7.5 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Meloxicam 10 mg capsule | Generic | $11.25 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $337.39 | +10% |
| Meloxicam 15 mg tablet | Generic | $0.0184 per tablet | $0.553 | -8% |
| Meloxicam 5 mg capsule | Generic | $8.92 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $267.68 | -22% |
| Meloxicam 7.5 mg tablet | Generic | $0.0166 per tablet | $0.497 | +0.8% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has meloxicam been recalled?
The FDA's Enforcement Report lists 5 recalls naming meloxicam since 2012: 0 Class I (the most serious), 5 Class II, 0 Class III; 1 still ongoing. 2 of them are by firms that FDA's NDC Directory does not list as a maker of meloxicam and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| January 26, 2022 | Class II | CARDINAL HEALTHCARE | CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. |
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
| April 23, 2015 | Class II | South Coast Specialty Compounding, Inc. not a listed maker | Penicillin Cross Contamination: Multiple finished products potentially contaminated with penicillin. |
| May 29, 2013 | Class II | Lowlite Investments, Inc. D/B/A Olympia Pharmacy not a listed maker | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes |
| April 5, 2012 | Class II | Apotex Corp. | Tablet Thickness: Recall was initiated due to the presence of one slightly oversized tablet in a bottle of the identified lot. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the meloxicam label say about other medicines?
The meloxicam label names 12 other medicines in its interaction, contraindication or warning sections. The labels of 16 other medicines name meloxicam. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amiodarone | drug interactions | CYP2C9 Inhibitors Clinical Impact: In vitro studies indicate that CYP2C9 (…) plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme. Thus concomitant usage of CYP2C9 inhibitors (…) may lead to abnormally high plasma levels of … Intervention: Consider dose reduction in patients undergoing treatment with CYP2C9 inhibitors, and monitor patients for adverse effects. |
| Aspirin | contraindications | … Warnings and Precautions (5.7, 5.9)] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. |
| Cyclosporine | drug interactions | Clinical Impact: Concomitant use of QAMZOVA and cyclosporine may increase cyclosporine’s nephrotoxicity. Intervention: During concomitant use of QAMZOVA and cyclosporine, monitor patients for signs of worsening renal function. NSAIDs and Salicylates |
| Diflunisal | drug interactions | NSAIDs and Salicylates Clinical Impact: Concomitant use of meloxicam with other NSAIDs or salicylates (…) increases the risk of GI toxicity, with little or no increase in efficacy [ see Warnings and Precautions () ]. Intervention: The concomitant use of meloxicam with other NSAIDs or salicylates is not recommended. |
| Fluconazole | drug interactions | CYP2C9 Inhibitors Clinical Impact: In vitro studies indicate that CYP2C9 (…) plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme. Thus concomitant usage of CYP2C9 inhibitors (…) may lead to abnormally high plasma levels of … Intervention: Consider dose reduction in patients undergoing treatment with CYP2C9 inhibitors, and monitor patients for adverse effects. |
| Furosemide | drug interactions | In such high risk patients, monitor for signs of worsening renal function (7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. |
| Lithium | drug interactions | Clinical Impact: NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. … Intervention: During concomitant use of QAMZOVA and lithium, monitor patients for signs of lithium toxicity. |
| Methotrexate | drug interactions | Methotrexate Clinical Impact: Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (…). Intervention: During concomitant use of QAMZOVA and methotrexate, monitor patients for methotrexate toxicity. |
| Pemetrexed | drug interactions | Pemetrexed Clinical Impact: Concomitant use of QAMZOVA and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). Intervention: During concomitant use of QAMZOVA and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. … |
| Propranolol | drug interactions | ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol). … Intervention: During concomitant use of QAMZOVA and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. … |
| Sodium polystyrene sulfonate | drug interactions | Sodium Polystyrene Sulfonate Clinical Impact: Cases of intestinal necrosis (possibly fatal) have been described in patients who received concomitant sorbitol and sodium polystyrene sulfonate. … Intervention: The concomitant use of meloxicam oral suspension with sodium polystyrene sulfonate is not recommended. |
| Warfarin | drug interactions | Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. |
Other labels that name meloxicam
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
What do FAERS reports show for meloxicam?
The FDA Adverse Event Reporting System holds 57,757 reports that list meloxicam among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 3,732 are coded as a death and 13,857 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as meloxicam?
29 other medicines are given the same way (oral) and in the same FDA class as meloxicam or labeled mainly for the same use (osteoarthritis), the same class first. Osteoarthritis lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Ibuprofen | Pain, Osteoarthritis, Rheumatoid arthritis | 273 labelers | $0.0573 per tablet 800 mg tablet | No current entry |
| Naproxen | Pain, Osteoarthritis, Rheumatoid arthritis | 146 labelers | $0.0565 per tablet 500 mg tablet | No current entry |
| Celecoxib | Pain, Osteoarthritis, Rheumatoid arthritis | 65 labelers | $0.0762 per capsule 200 mg capsule | No current entry |
| Diclofenac | Pain, Osteoarthritis, Rheumatoid arthritis | 67 labelers | $0.0619 per tablet 75 mg tablet | A presentation being discontinued |
| Acetaminophen and aspirin and caffeine | Pain | 39 labelers | $0.0648 per unit 250-250-65 mg cplt | No current entry |
| Etodolac | Pain, Osteoarthritis, Rheumatoid arthritis | 30 labelers | $0.262 per tablet 400 mg tablet | No current entry |
| Acetaminophen and ibuprofen | Pain | 51 labelers | $0.107 per unit 250-125 mg | No current entry |
| Indomethacin | Osteoarthritis, Rheumatoid arthritis | 25 labelers | $0.210 per capsule 75 mg capsule | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does meloxicam compare with medicines for the same use?
24 side-by-side pages set meloxicam beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to meloxicam
- 29 medicines for the same use
- Other NSAIDs
- the pharmacologic class, with prices and generics
- Meloxicam side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other